Biocon
Herceptin faces UK competition within months
April 11, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Biocon, Herceptin, Hospira, Perjeta, breast cancer
Roche’s blockbuster breast cancer drug Herceptin may soon be under threat from copycat treatments after a court in the UK …
Novartis sues Biocon
April 4, 2014Sales and Marketing Biocon, Galvus, Gilead, Herceptin, Novartis, sofosbuvir
India’s status as a battleground for patent issues has been reinforced with the news that Novartis is suing Biocon over …
India court grants Herceptin injunction
February 10, 2014Research and Development, Sales and Marketing Biocon, Herceptin, India, Mylan, Roche
Roche has been granted an injunction by a court in India to prevent generic manufacturers of its ageing breast cancer …
Herceptin biosimilar set for Indian market
January 21, 2014Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab
Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …
Insulin blockbusters targeted by biosimilar blitz
February 15, 2013Research and Development, Sales and Marketing Biocon, Humalog, Mylan, insulin
Mylan and Biocon are the latest companies to announce major new plans to develop and market biosimilars. The firms are …
Pfizer pulls out of $350 million insulin pact
March 14, 2012Research and Development, Sales and Marketing Biocon, Humalog, Lantus, NovoLog, Pfizer
Pfizer has walked away from a research deal with India’s biggest biotech firm Biocon. Both companies were working on a …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
